Less than a year ago, Eli Lilly and Co. and Isis Pharmaceuticals Inc. signed a deal for Isis' antisense technology worth as much as $400 million. On Tuesday the companies expanded that deal, opening it up to include specific gene targets for cancer and adding to its total value. (BioWorld Today) Read More
